The DNA-damaging potential of tamoxifen in breast cancer and normal cells

Archives of Toxicology

Volumn 81, Issue 7, 2007, Pages 519-527

  Wozniak, Katarzyna ^a   Kolacinska, Agnieszka ^b   Blasinska Morawiec, Maria ^b   Morawiec Bajda, Alina ^c   Morawiec, Zbigniew ^b   Zadrozny, Marek ^b   Blasiak, Janusz ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amifostine; Breast cancer; Comet assay; DNA damage; DNA repair; Genistein; Human lymphocytes; MCF 7 cells; Tamoxifen; Vitamin C

Indexed keywords

AMIFOSTINE; ASCORBIC ACID; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; ENDONUCLEASE III; ENZYME; FREE RADICAL; GENISTEIN; NITRONE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SCAVENGER; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; BREAST CANCER; CANCER CELL; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; PRIORITY JOURNAL;

ADULT; AMIFOSTINE; ASCORBIC ACID; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA-FORMAMIDOPYRIMIDINE GLYCOSYLASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDODEOXYRIBONUCLEASES; ESTROGEN RECEPTOR MODULATORS; FEMALE; FREE RADICAL SCAVENGERS; GENISTEIN; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LYMPHOCYTES; MALE; MUTAGENS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TAMOXIFEN;

EID: 34347344970     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00204-007-0188-3     Document Type: Article

References (36)

1. Ashby JA, Tinwell H, Lefevre PA, Browne MA (1995) The single cell gel electrophoresis assay for induced DNA damage (comet assay): measurement of tail length and moment. Mutagenesis 10:85-90
2. Belzile JP, Choudhury SA, Cournoyer D, Chow TY (2006) Targeting DNA-repair proteins a promising avenue for cancer gene therapy. Curr Gene Ther 6:111-123
3. Blasiak J, Kowalik J (2000) A comparison of the in vitro genotoxicity of tri- and hexavalent chromium. Mutat Res 469:135-145
4. Blasiak J, Gloc E, Mlynarski W, Drzewoski J, Skorski T (2002) Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leukemia Res 26:1093-1096
5. Blasiak J, Gloc E, Drzewoski J, Wozniak K, Zadrozny M, Skorski T, Pertynski T (2003) Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells. Mutat Res 535:25-34
6. Clemons M, Danson S, Howell A (2002) Tamoxifen (Nolvadex): a review. Cancer Treat Rev 28:165-180
7. Collins AR, Duthie SJ, Dobson VL (1993) Direct enzymatic detection of endogenous base damage in human lymphocyte DNA. Carcinogenesis 14:1733-1735
8. Ding J, Miao ZH, Meng LH, Geng MY (2006) Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 27:338-344
9. Evans MD, Podmore ID, Daly GJ, Perrett D, Lunec J, Herbert KE (1995) Detection of purine lesions in cellular DNA using single cell gel electrophoresis with Fpg protein. Biochem Soc Trans 23:434S
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90:1371-1388
11. Giatromanolaki A, Sivridis E, Maltezos E, Koukourakis MI (2002) Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol 29:14-21
12. Grdina DJ, Kataoka Y, Murley JS (2000) Amifostine: mechanism of action underlying cytoprotection and chemoprevention. Drug Metab Drug Interact 16:237-279
13. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T (1993) Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924
14. Han XL, Liehr JG (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363
15. IARC (1996) Tamoxifen. In IARC Monographs on the evolution of carcinogenic risks to humans, No. 66, Some Pharmaceutical Drugs. IARC, Lyon, pp 253-365
16. Klaude M, Eriksson S, Nygren J, Ahnstrom G (1996) The comet assay: mechanisms and technical considerations. Mutat Res 363:89-96
17. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. J Biol Chem 275:33585-33592
18. Krokan HE, Standal R, Slupphaug G (1997) DNA glycosylases in the base excision repair. Biochem J 325:1-16
19. Lim CK, Yuan Z-X, Lamb JH, White IN, De Matteis F, Smith LL (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15:589-593
20. Lindahl T (1993) Instability and decay of the primary structure of DNA. Nature 362:709-715
21. Loft S, Poulsen HE (1996) Cancer risk and oxidative DNA damage in man. J Mol Med 74:297-312
22. Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, Smith LL, White INH (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 63:8461-8465
23. McCall MR, Frei B (1999) Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 26:1034-1053
24. Miura T, Muraoka S, Fujimoto Y, Zhao K (2000) DNA strand break and 8-hydroxyguanine formation induced by 2-hydroxyestradiol dispersed in liposomes. J Steroid Biochem Mol Biol 74:93-98
25. Mizutani A, Okada T, Shibutani S, Sonoda E, Hochegger H, Nishigori Ch, Miyachi Y, Takeda S, Yamazoe M (2004) Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res 64:3144-3147
26. Obrero M, Yu DV, Shapiro DJ (2002) Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen- induced programmed cell death. J Biol Chem 277:45695-45703
27. Pagano G, de Biase A, Deeva IB, Degan P, Doronin YK, Iaccarino M, Oral R, Trieff NM, Warnau M, Korkina LG (2001) The role of oxidative stress in developmental and reproductive toxicity of tamoxifen. Life Sci 68:1735-1749
28. Phillips DH (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22:839-849
29. Poirier MC, Schild LJ (2003) The genotoxicity of tamoxifen: extent and consequences, Kona Hawaii, January 23, 2003. Mutagenesis 18:395-399
30. Poon GK, Chui YC, McCague R, Llnning PE, Feng R, Rowlands MG, Jarman M (1993) Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 21:1119-1124
31. Salami S, Karami-Tehrani F (2003) Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem 36:247-253
32. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
33. Sharma M, Shubert DE, Sharma M, Rodabaugh KJ, McGarrigle BP, Vezina ChM, Bofinger DP, Olson JR (2003) Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. Biochem Biophys Res Commun 307:157-164
34. Singh NP, McCoy T, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-192
35. Singh NP, Stephens RE (1997) Microgel electrophoresis: sensitivity, mechanisms and DNA electrostretching. Mutat Res 383:671-675
36. Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T (2002) Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Obstet Gynecol 102:188-194